Abstracts tagged "population studies"

Abstract Number: 0820 • ACR Convergence 2022
Therapeutic Practices and Outcomes of Chronic Sarcoidosis Arthropathy in the United States: A Nationwide Registry Study
Diala Alawneh¹, Moustafa Younis², Bashar Alzghoul², Christian Ascoli¹, Tricha Shivas³, Mary McGowan³, Khaldoon Alawneh⁴, Divya Patel², Israel Rubinstein¹ and Nadera Sweiss¹, ¹University of Illinois at Chicago, Chicago, IL, ²University of Florida, Gainesville, FL, ³Foundation for Sarcoidosis Research, Chicago, IL, ⁴Jordan University of Science and Technology, Irbid, Jordan
Background/Purpose: Chronic arthropathy is a rare manifestation of sarcoidosis reported in only 0.2% of patients. However, treatment is challenging because no general consensus regarding appropriate…
Abstract Number: 1271 • ACR Convergence 2021
Healthcare Resource Utilization and Costs Associated with Systemic Lupus Erythematosus After Diagnosis of End-Stage Kidney Disease: Evidence from Two United States Databases
Shirley Huang¹, Amy Guisinger² and Christopher Bell¹, ¹GlaxoSmithKline, Research Triangle Park, NC, ²US Value, Evidence and Outcomes, GlaxoSmithKline, Research Triangle Park, NC
Background/Purpose: Approximately 40% of patients with systemic lupus erythematosus (SLE) develop lupus nephritis (LN), of whom up to 20% may progress to end-stage kidney disease…
Abstract Number: 1286 • ACR Convergence 2021
Twenty-Year Trends in Systemic Lupus Erythematosus All–Cause Mortality in Mexico: A Nationwide Health Registry
Claudia Mendoza-Pinto¹, Ivet Etchegaray-Morales², Mario García-Carrasco², Pamela Munguía-Realpozo² and Socorro Méndez-Martínez³, ¹Instituto Mexicano del Seguro Social, San Andres Cholula, Mexico, ²Benemérita Universidad Autónoma de Puebla, Puebla, Mexico, ³Instituto Mexicano del Seguro Social, Puebla, Mexico
Background/Purpose: Marked regional variation in systemic lupus erythematosus (SLE) mortality may be due to different spectra of local environmental factors. There have been no large…
Abstract Number: 1579 • ACR Convergence 2021
Phenome-Wide Association of Gout Risk Loci
Oleg Stens¹, Vivian Trang², Steven Cao², Robert Terkeltaub¹ and Rany Salem², ¹University of California San Diego School of Medicine, La Jolla, CA, ²University of California San Diego School of Public Health, La Jolla, CA
Background/Purpose: Gout is a complex disease involving changes in urate biology and inflammatory responses, and is associated with comorbidities including metabolic syndrome and cardiorenal disease.…
Abstract Number: 1663 • ACR Convergence 2021
The Influence of Comorbidity on Mortality in Patients with Rheumatoid Arthritis 1980-2015: A Longitudinal Population-based Study in Western Australia
Khalid Almutairi¹, Johannes Nossent¹, David Preen¹, Helen Keen² and Charles Inderjeeth³, ¹University of Western Australia, Perth, Australia, ²University of Western Australia, Daglish, Australia, ³University of Western Australia, Nedlands, Perth, Australia
Background/Purpose: Rheumatoid arthritis (RA) contributes to excess morbidity and mortality in RA patients compared with the general population. In Australia, there is a paucity of…
Abstract Number: 0111 • ACR Convergence 2021
Risk of Hospitalization, Admission to Intensive Care and Mortality Due to COVID-19 in Patients with Rheumatic Diseases: A Population-based Matched Cohort Study
Ana Michelle Avina-Galindo¹, Shelby Marozoff¹, Zahra Fazal¹, Jessie Kwan¹, Na Lu¹, Alison Hoens², Diane Lacaille³, Jacek Kopec⁴, Hui Xie⁵ and J. Antonio Avina-Zubieta³, ¹Arthritis Research Canada, Vancouver, BC, Canada, ²Arthritis Research Canada Arthritis Patient Advisory Board, Vancouver, BC, Canada, ³Arthritis Research Canada, Richmond, BC, Canada, ⁴University of British Columbia, Richmond, BC, Canada, ⁵Simon Fraser University, Burnaby, BC, Canada
Background/Purpose: New cases of the novel coronavirus disease (COVID-19) continue to occur even one year since the declaration of a global pandemic. Although most people…
Abstract Number: 1909 • ACR Convergence 2021
Impact of Antimalarial Adherence on Cardiovascular Mortality Among Patients with Newly Diagnosed Rheumatoid Arthritis and Systemic Lupus Erythematosus: A Population-based Study
Md Rashedul Hoque¹, J. Antonio Avina-Zubieta², Diane Lacaille², Mary De Vera³, Yi Qian³, John Esdaile⁴ and Hui Xie⁵, ¹Simon Fraser University, Vancouver, BC, Canada, ²Arthritis Research Canada, Richmond, BC, Canada, ³University of British Columbia, Vancouver, BC, Canada, ⁴Arthritis Research Canada, Vancouver, BC, Canada, ⁵Simon Fraser University, Burnaby, BC, Canada
Background/Purpose: Literature has shown poor adherence to antimalarial (AM) medications in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) patients, with the percentage of adherers…
Abstract Number: 0132 • ACR Convergence 2021
Hospitalization Rates Among Patients with Systemic Lupus Erythematosus: A Population Based Study
Jesse Dabit¹, Mehmet Hocaoglu², Maria Valenzuela-Almada³, Shirley-Ann Osei-Onomah¹, Sebastian Vallejo-Ramos¹, Rachel Giblon¹, Kurt Greenlund⁴, Kamil Barbour⁴, Cynthia Crowson⁵ and Ali Duarte-Garcia¹, ¹Mayo Clinic, Rochester, MN, ²University of Maryland Medical Center, Midtown Campus, Baltimore, MD, ³Division of Rheumatology, Mayo Clinic, Rochester, MN, ⁴Centers for Disease Control, Atlanta, GA, ⁵Mayo Clinic, Eyota, MN
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune multiorgan disease associated with significant morbidity and mortality. Although the survival rate for SLE patients has…
Abstract Number: 1925 • ACR Convergence 2021
Risk of Heart Failure in Patients with Inflammatory Disease: A Population-Based Study
Sahil Koppikar¹, Bindee Kuriya², Jacob Udell³, Bing Yu⁴, Anna Chu⁴, Laura Ferreira-Legere⁵, Douglas Lee³, Jessica Widdifield⁶ and Lihi Eder³, ¹Women's College Hospital, Toronto, ON, Canada, ²University of Toronto - Toronto, Toronto, ON, Canada, ³University of Toronto, Toronto, ON, Canada, ⁴ICES, Toronto, ON, Canada, ⁵ICES, Toronto, Canada, ⁶Sunnybrook Research Institute; ICES; Institute of Health Policy, Management & Evaluation, University of Toronto, Toronto, ON, Canada
Background/Purpose: Individuals with inflammatory diseases (ID) have an increased risk of cardiovascular disease, frequently compared to that of diabetes mellitus (DM). However, the magnitude of…
Abstract Number: 0332 • ACR Convergence 2021
Prevalence of Systemic Lupus Erythematosus in the United States: Updated Population Representative Estimates from the Medical Expenditure Panel Survey (MEPS) 2016-2018
Michael Pollack¹, Sandra Sze-jung Wu¹, Eilleen Farrelly², Shannon Grabich³ and Robert Ortmann⁴, ¹AstraZeneca, Wilmington, DE, ²Xcenda, Carrollton, TX, ³Xcenda, Durham, NC, ⁴AstraZeneca, Greenwood, IN
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic, multi-organ, autoimmune disease whose prevalence in the US has not been recently updated in real-world studies. Prevalence…
Abstract Number: 0377 • ACR Convergence 2021
The Prevalence of Inflammatory Back Pain and HLA-B27 in a Large Population-Based Cohort in the Netherlands
Stan Kieskamp, Suzanne Arends, Elisabeth Brouwer, Hendrika Bootsma, Ilja Nolte and Anneke Spoorenberg, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Chronic low back pain (CLBP; back pain >3 months) with onset at age < 45 and inflammatory back pain (IBP) are regarded as early…
Abstract Number: 0591 • ACR Convergence 2021
The Temporal Association Between Hospital Admissions, Disease-modifying Anti-rheumatic Drugs Usage and Direct Health Care Costs in Rheumatoid Arthritis Patients
Khalid Almutairi¹, Johannes Nossent¹, David Preen¹, Helen Keen² and Charles Inderjeeth³, ¹University of Western Australia, Perth, Australia, ²University of Western Australia, Daglish, Australia, ³University of Western Australia, Nedlands, Perth, Australia
Background/Purpose: Rheumatoid arthritis (RA) carries a substantial burden for patients and society in terms of morbidity, disability, and medical expenses. The Australian Pharmaceutical Benefits Scheme…
Abstract Number: 0593 • ACR Convergence 2021
Labour Force Participation Among Individuals with Osteoarthritis, Rheumatoid Arthritis/Other Arthritis Types, or with Joint Symptoms but Without a Diagnosis: An Age-Stratified Population-Based Study
Shatabdy Zahid, Elizabeth Badley and Anthony Perruccio, Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada
Background/Purpose: Having arthritis is known to affect labour force participation. Most research has focused on individuals with doctor-diagnosed rheumatoid arthritis (RA) and, to a lesser…
Abstract Number: 0689 • ACR Convergence 2021
Incidence, Prevalence, and Mortality of Dermatomyositis: A Population-based Cohort
Vanessa Kronzer¹, Bradly Kimbrough², Cynthia Crowson³, John Davis¹, Marie Holmqvist⁴ and Floranne Ernste¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic Rochester, Rochester, MN, ³Mayo Clinic, Eyota, MN, ⁴Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Previous epidemiologic studies defined dermatomyositis (DM) using international codes of diseases (ICD) codes or Bohan & Peter 1975 criteria, and most were not population-based.…
Abstract Number: 1022 • ACR Convergence 2021
Incidence of Antisynthetase Syndrome and Risk of Malignancy in a Population-based Cohort (1998-2019)
Caitrin Coffey¹, Li Wang¹, Stephanie Duong¹, Cassondra Hulshizer¹, Cynthia Crowson², Jay Ryu¹ and Floranne Ernste¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Eyota, MN
Background/Purpose: The antisynthetase syndrome (ASSD) is a distinct subgroup of the idiopathic inflammatory myopathies characterized by myositis, interstitial lung disease, inflammatory arthritis, Raynaud’s phenomenon and…

« Previous Page
1
…
5
6
7
8
9
…
11
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].